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Background. We evaluated the prevalence of chronic hepatitis B virus (HBV) infection and liver ﬁbrosis/cirrhosis in human
immunodeﬁciency virus (HIV)-infected individuals enrolled in a rural Tanzanian prospective cohort and assessed hepatic ﬁbrosis
progression 12–24 months after antiretroviral treatment (ART) initiation.
Methods. All ART-naive HIV-infected adults ≥15-year-old enrolled in the Kilombero and Ulanga Antiretroviral Cohort who
started ART between 2005 and 2015 were included. Pre-ART factors associated with signiﬁcant liver ﬁbrosis (aspartate aminotrans-
ferase-to-platelet ratio index [APRI] >1.5) and cirrhosis (APRI > 2.0) were identiﬁed using logistic regression.
Results. Of 3097 individuals screened, 227 (7.3%; 95% CI, 6.4–8.2) were hepatitis B surface antigen (HBsAg) positive. Before
ART initiation, 9.1% individuals had signiﬁcant liver ﬁbrosis and 5.3% had cirrhosis. Human immunodeﬁciency virus/HBV-
coinfected individuals were more likely to have an APRI score indicating signiﬁcant ﬁbrosis (14.2% vs 8.7%, P = .03) and cirrhosis
(9.2% vs 4.9%, P = .03) than HBV-uninfected patients. CD4 cell count <200 cell/μL and alcohol consumption were independently
associated with pre-ART APRI score, indicating signiﬁcant ﬁbrosis and cirrhosis in multivariable analyses. Among individuals with
elevated APRI measurements pre- and 12–24 months post-ART initiation, 53 of 57 (93.0%) of HIV-monoinfected and 4 of 5 (80.0%)
of HIV/HBV-coinfected had a regression to APRI < 1.5.
Conclusions. Hepatic ﬁbrosis and cirrhosis were common in our cohort, especially among HIV/HBV-coinfected individuals.
The APRI improved in most patients. Pre-ART HBsAg screening and early onset of tenofovir-based ART for HIV/HBV-coinfection
should be prioritized in sub-Saharan Africa.
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Antiretroviral therapy (ART) has improved survival rates
among persons living with human immunodeﬁciency virus
(PLWHIV) in sub-Saharan Africa (SSA). As survival increases,
other comorbidities such as infection by hepatitis B virus
(HBV) are emerging as important causes of morbidity and mor-
tality in this population. Up to 15% of PLWHIV are infected
with HBV in SSA [1]. In Tanzania, serum hepatitis B surface
antigen (HBsAg) prevalence has been reported to be up to
17.3% [2, 3] and in rural areas up to 9.2% among HIV-infected
individuals [4]. Although impact of HBV on HIV progression is
less clear, several non-African and African cohort studies
strongly suggest that HIV-individuals are at increased mortality
when coinfected with HBV [5–7]. Hepatitis B virus coinfection
could impair immunological recovery and increase risk of
hepatotoxicity [8] and has been identiﬁed as the main aetiolog-
ical agent for hepatocellular carcinoma (HCC) in small African
cohorts [9, 10].
Current World Health Organization (WHO) guidelines for
the prevention, care, and treatment of persons with chronic
hepatitis B infection recommend aspartate aminotransferase
(AST)-to-platelet ratio index (APRI) as the preferred noninva-
sive test to assess for the presence of cirrhosis in resource-
limited settings, as an alternative to more expensive and often
not available options such as transient elastography (TE) and
liver biopsy [11]. Noninvasive tests of liver ﬁbrosis have been
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poorly studied in chronic hepatitis B in SSA [12, 13], and very
few have assessed the progression of hepatic ﬁbrosis after ART ini-
tiation. Prior data from cross-sectional studies in SSA using TE
have reported a high prevalence of liver disease in both HIV-
monoinfected and HIV/HBV-coinfected [14,15].However, the re-
gression of liver ﬁbrosis and cirrhosis assessed by liver biopsy has
only been demonstrated in HBV-monoinfected to date [16, 17].
In this study conducted in a rural Tanzanian cohort of
PLWHIV initiating ART, we investigated the prevalence of HBV
coinfection and hepatic ﬁbrosis/cirrhosis using APRI, and we
evaluated the progression of liver ﬁbrosis after ART initiation.
METHODS
Study Setting and Population
The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO)
is an ongoing, open, prospective cohort that comprises all pa-
tients who visit the Chronic Diseases Clinic of Ifakara (CDCI)
within the Saint Francis Referral Hospital (SFRH) and provide
their written informed consent to participate. More details
about the KIULARCO are given elsewhere [18–20]. The
SFRH is the largest healthcare facility in the Kilombero district
of the Morogoro region in southern Tanzania, providing treat-
ment and care for a population of approximately 600 000
inhabitants and an estimated 30 000 patients living with HIV/
acquired immune deﬁciency syndrome (AIDS). Established in
2004, this was the ﬁrst rural clinic accredited to be a Care and
Treatment Centre of the National AIDS Control Program in
Tanzania, and more than 9000 patients have been enrolled
into care. Participants are followed-up as per national standard
of care guidelines. Medical histories, physical examination,
laboratory tests, and blood samples are obtained at the time
of registration in the clinic, before ART initiation, 2 weeks
and 3 months after ART initiation, and every 6 months there-
after. Plasma from blood samples is collected at every clinical
visit and cryopreserved at −80°C.
For this study, we included all adult (>15 years) ART-naive
PLWHIV enrolled in KIULARCO since January 2005, under
active follow-up in November 2015 and with an available
HBsAg result. Participants on ART before enrollment, those
who did not provide informed consent, and those without an
HBsAg test were excluded for the analysis. Among the eligible
individuals, we excluded those with missing platelet (PLT)
values and/or AST for regression analysis. Subsequently, we
excluded HIV-individuals that remained ART-naive by Novem-
ber 2015, those with <12 months of follow-up since enrollment,
those with a missing post-ARTAPRI, and those on ART for <12
months for analysis of APRI score change.
Deﬁnitions
Hepatitis B Virus Status
The HBsAg was detected by Determine HBsAg (Alere Inc.,
Waltham, MA). Analysis were performed on cryopreserved
plasma samples from patients enrolled before January 2013
and from 1 blood draw per subject after January 2013. Because
seroconversion of HBsAg (complete clearance of HBsAg) is
exceptional even in the presence of HBV-suppressive agents,
we assumed that all patients with a positive HBsAg test were
already HBV-infected at enrollment in the cohort [21]. Among
patients enrolled before January 2013, ART had been previously
initiated following current Tanzanian National ART Guidelines
in the absence of HBsAg data. Those who tested positive were
consequently switched to an ART regimen including tenofovir
disoproxil fumarate (TDF) combined with either lamivudine
(3TC) or emtricitabine (FTC).
Alcohol Consumption
Participants were asked to answer “yes” or “no” to the questions
“Do you regularly drink alcohol?” and to give the “number of
standard drinks per day”. Alcohol consumption was deﬁned
as a positive answer to the ﬁrst question and a value ≥1 to
the second question. In addition, we quantiﬁed the number of
standard drinks per day and considered “Heavy alcohol drink-
ing” as the consumption of 4 or more standard drinks for men
and 3 or more for women.
Liver Fibrosis
We assessed liver ﬁbrosis using APRI score, and values thresh-
olds used were >1.5 for signiﬁcant hepatic ﬁbrosis and >2.0 for
cirrhosis, as recommended by the WHO [11]. The upper limit
of the norm for AST was 40 IU/L. The APRI was calculated pre-
ART (before or within 3 months of ART initiation) in patients
who started ART and at the most recent clinical visit for those
who did not start ART during the follow up. Thereafter, APRI
was calculated at 12 months (post-ART) after ART initiation
(window from 12 to 24 months). We deﬁned “Regression to
APRI ;< 1.5” as a change from APRI ≥ 1.5 at baseline to <1.5
at 12–24 months after ART initiation, and we deﬁned “Progres-
sion to APRI ;> 1.5” as a change from APRI ;≤ 1.5 at baseline to
>1.5 at 12–24 months after ART initiation.
Statistical Analysis
Baseline characteristics between HIV-monoinfected and HIV/
HBV-coinfected were compared using the χ2 and/or Fisher
exact tests for categorical variables and the Wilcoxon non-
parametric test for continuous variables. Univariate and multi-
variate logistic regression analysis were used to estimate the
association between covariates and APRI score indicating sig-
niﬁcant ﬁbrosis and cirrhosis. We adjusted the multivariate
model for age (continuous) and found it to be nonlinear, so
we included the squared term. We could not use tuberculosis
(TB) drugs in the model, because there was no patient on TB
drugs included in the ﬁnal model. Results were presented
with odds ratios (OR) and 95% conﬁdence intervals (CIs).
We compared APRI score change between HIV-monoinfected
and HIV/HBV-coinfected in a subset of individuals with both
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pre- and post-ARTAPRI measurements and APRI score >1.5 at
baseline using the χ2 and/or Fisher exact test. Statistical analyses
were performed using Stata 14 software (StataCorp, Houston,
TX).
Ethical Considerations
Written informed consent was sought from all participants at
registration at the CDCI, and all data were deidentiﬁed. Samples
were collected during routine clinical visits, and ethical approval
for its cryopreservation and retrospective analysis was obtained
from the Ifakara Health Institute institutional review board, the
National Health Research Ethics Review Committee of the Na-
tional Institute for Medical Research of Tanzania, the Tanzani-
an Commission of Science and Technology, and the Ethics
Committee of the University and State of Basel, Switzerland.
RESULTS
From January 2005 to November 2015, a total of 3097 HIV-
infected individuals were eligible for the study analysis (see Sup-
plementary Figure 1). Of those, 227 (7.3%) were HBsAg positive.
The APRI at baseline was available for 1707 of 3097 (55.1%) indi-
viduals, 1566 of 2870 (56.6%) in the HIV-monoinfected group
and 141 of 227 (62.1%) in the HIV/HBV-coinfected group.
Among them, 500 of 1707 (29.3%) had both pre-ART and post-
ARTAPRI after excluding participants who remained ART-naive
after 24 months of follow up and those on ART for <12 months.
Of these, 44 of 500 (8.8%) were HIV/HBV-coinfected. Main
characteristics of excluded individuals did not differ remarkably
from eligible individuals except for the fact that more than 70%
of them started with 3TC without TDF (see Supplementary
Table 1). The majority of them were enrolled before 2012, when
TDF was not yet included as ﬁrst-line ART regimen in the
Tanzanian National Guidelines.
Baseline Characteristics
Baseline characteristics of the study population are summarized
in Table 1. Approximately three quarters of participants were
female, in greater percentage in the HIV-monoinfected group
compared with the HIV/HBV-coinfected group (68.3% vs
52.0%, respectively). Median CD4 cell count and percentage
of all individuals at ART initiation was low: 185 cell/μL (inter-
quartile range [IQR], 84–302) and 10% (IQR, 4–18) with no dif-
ferences between groups. Overall, 10.5% of HIV-individuals had
PLT < 150 × 109/L, although this proportion was higher in HIV/
HBV-coinfected compared with HIV-monoinfected (17.9% vs
9.9%). Alcohol consumption was self-reported in 25.2% of all
participants, and 7.4% of them were classiﬁed as heavy drinkers.
Eleven percent of all individuals did not initiate ART during the
follow-up period, with a higher proportion remaining ART-
naive in the HIV-monoinfected group compared with the
HIV/HBV-coinfected group (11.4% vs 7.1%, respectively).
Among the 2753 individuals who initiated ART, 1463 (53.1%)
received y as the sole HBV-active drug and 1099 (39.9%)
received TDF in combination with either FTC or 3TC as initial
ART.
Prevalence of Aspartate Aminotransferase-to-Platelet Ratio Index
Score Indicating Signiﬁcant Fibrosis and Cirrhosis
Among individuals with available pre-ART APRI, 156 of 1707
(9.1%) had APRI score indicating signiﬁcant ﬁbrosis and 90 of
1707 (5.3%) had APRI score indicating cirrhosis at baseline.
Human immunodeﬁciency virus/HBV-coinfected individuals
exhibited higher median APRI score than HIV-monoinfected
(0.57 [IQR, 0.32–1.08] vs 0.37 [IQR, 0.22–0.77], P < .001).
The prevalence of APRI score indicating signiﬁcant ﬁbrosis
(APRI > 1.5) and cirrhosis (APRI > 2) among HIV/HBV-coin-
fected was 14.2% and 9.2%, and it was signiﬁcantly higher than
in HIV-monoinfected (8.7% [P = .03] and 4.9% [P = .03], re-
spectively) (Table 2).
Risk Factors for Aspartate Aminotransferase-to-Platelet Ratio Index
Score Indicating Signiﬁcant Fibrosis
Baseline variables that were associated with signiﬁcant liver ﬁ-
brosis in the univariable analyses were HBsAg positivity
(OR = 1.73; 95% CI, 1.05–2.88; P = .03), CD4 cell count <200
cells/µL (OR = 1.82; 95% CI, 1.25–2.68; P = .002), and alcohol
consumption (OR = 1.63; 95% CI, 1.13–2.36; P = .01). In the
multivariable analysis, only CD4 < 200 cells/µL (OR = 1.72;
95% CI, 1.16–2.54; P = .007) and alcohol consumption
(OR = 1.60; 95% CI, 1.06–2.40; P = .03) remained independent-
ly associated with APRI score >1.5 at baseline (Table 3). All
models were adjusted for age, which exhibited a signiﬁcant non-
linear effect with both younger and older individuals exhibiting
higher risk of ﬁbrosis and cirrhosis.
Aspartate Aminotransferase-to-Platelet Ratio Index Score Changes
in Patients on Antiretroviral Therapy
Of the 500 individuals with pre- and post-ART APRI, 62 of 500
(12.4%) had APRI > 1.5 at baseline and 34 of 500 (6.8%) had
APRI > 2 (see Supplementary Table 2). Overall, 426 of 500
(85.2%) did not experience an APRI score change at 12–24
months on ART. Otherwise, the proportion of individuals
with APRI > 1.5 decreased after ART initiation in both HIV-
and HIV/HBV-infected groups. There was a decline in median
APRI from baseline to the 12–24 months measurement for all
individuals (P < .001) including HIV-monoinfected (P < .001)
and HIV/HBV-coinfected (P = .45). Among 62 of 500 (12.4%)
individuals with APRI score indicating signiﬁcant ﬁbrosis at
baseline, we observed a regression to APRI < 1.5 in 57 of 62
(92.0%) of them, 53 of 62 (84.5%) were HIV-monoinfected
and 4 of 62 (6.5%) were HIV/HBV-coinfected (Figure 1).
Only 4 of 62 (6.5%) individuals with APRI > 1.5 at baseline pro-
gressed to APRI > 2 post-ART, and 3 of 62 (4.8%) remained
with APRI > 1.5.
Regression to APRI < 1.5 was observed in 53 of 57 (93.0%) of
HIV-monoinfected and in 4 of 5 (80%) HIV/HBV-coinfected
individuals. Furthermore, of 34 of 500 (6.8%) with cirrhosis at
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baseline, regression to APRI < 2 was observed in 2 of 2 (100%)
of HIV/HBV-coinfected and in 29 of 32 (90.6%) of HIV-
monoinfected. In contrast, 17 of 438 (3.9%) of HIV-infected
individuals progressed to APRI > 1.5, 16 of 438 (3.7%) HIV-
monoinfected and 1 of 438 (0.7%) HIV/HBV-coinfected.
Aspartate Aminotransferase-to-Platelet Ratio Index Variation by
Treatment Regimen
Among the 62 individuals with APRI > 1.5 at baseline, 44 of 62
(71.0%) had initiated ART with 3TC as the sole drug with dual
activity against HIV and HBV, and 16 of 62 (25.8%) initiated
ART with TDF either in combination with FTC or 3TC. Among
HIV/HBV-coinfected individuals with pre-ART APRI > 1.5 who
initiated ART, 1 of 1 (100%) on TDF and 3 of 4 (75%) without
TDF regressed to APRI < 1.5 after 12–24 months of ART
initiation.
DISCUSSION
Few studies have evaluated liver ﬁbrosis using APRI in ART-
naive individuals in SSA and its variation after ART initiation.
Key ﬁndings of our study include a high prevalence of APRI
score indicating signiﬁcant ﬁbrosis and cirrhosis among ART-
naive HIV-infected individuals in rural Tanzania, particularly
among HBsAg-positive individuals, and a regression of APRI
to <1.5 after 12–24 months of ART, irrespective of HBV-
infection status in the majority of participants with elevated
APRI scores.
Table 1. Pre-ART Characteristics of Individuals by Infection Status
Characteristic
Infection Status
All (n = 3097) HIV Monoinfected (n = 2870) HIV/HBV Coinfected (n = 227)
Female gender (n [%]) 2078 (77.1) 1960 (68.3) 118 (52.0)
Pregnanta (n [%]) 122 (7.1) 118 (7.3) 4 (4.0)
Age (median [IQR]), years 38.0 (31.0–45.6) 38.1 (31.8–45.6) 37.0 (31.7–45.4)
Alcohol useb (n [%]) 730 (25.2) 671 (24.9) 60 (28.2)
Heavy drinkersc (n [%]) 14 (7.4) 13 (7.6) 1 (5.6)
BMId (median [IQR]), kg/m2 21.0 (18.9–23.4) 21.0 (18.9–23.5) 20.5 (18.3–23.9)
ART naive (n [%]) 344 (11.1) 328 (11.4) 16 (7.1)
ART regimen at initiatione (n [%])
3TC monotherapy 1463 (53.1) 1355 (53.3) 108 (51.2)
TDF + 3TC 645 (23.4) 584 (23.0) 61 (28.9)
TDF + FTC 454 (16.5) 422 (16.6) 32 (15.2)
Other 191 (6.9) 181 (7.1) 10 (4.7)
WHO stage at ART startf (n [%])
1 or 2 1415 (56.6) 1310 (56.8) 105 (54.4)
3 or 4 1084 (43.4) 996 (43.2) 88 (45.6)
CD4 count baselineg (median [IQR]), cells/µL 215 (89–404) 218 (90–405) 185 (65–365)
CD4 count baselineh (median [IQR]), % 12 (5–21) 12 (5–21) 12 (4–19)
CD4 count pre-ARTi (median [IQR]), cells/µL 185 (84–302) 185 (85–303) 183 (63–296)
CD4 count pre-ARTj (median [IQR]), % 10 (4–18) 10 (4–18) 10 (4–18)
Use of antituberculous drugsk (n [%]) 86 (2.8) 77 (2.7) 9 (4.0)
PLT < 150 × 109/Ll (n [%]) 179 (10.5) 154 (9.9) 25 (17.9)
PLT (median [IQR]), 109/L 250 (183–322) 252 (186–323) 220 (159–307)
ASTm (median [IQR]), U/L 53 (29–92) 53 (29–93) 56 (32–86)
Abbreviations: APRI, aspartate aminotransferase-to-platelet ratio; ART, antiretroviral therapy; BMI, body mass index; FTC, emtricitabine; HBV, hepatitis B infection; HIV, human
immunodeficiency virus; IQR, interquartile range; PLT, platelet; TDF, tenofovir disoproxil fumarate; WHO, World Health Organization; 3TC, lamivudine.
a Pregnancy status was available for 1728 individuals.
b Information on alcohol consumption at baseline was available for 2903 individuals.
c Alcohol amounts were available for 190 current drinkers individuals.
d BMI was available for 2353 individuals.
e ART regimen at initiation was available for 2753 individuals.
f WHO stage at ART initiation was available for 2499 individuals.
g CD4 cell count at baseline was available for 2189 individuals.
h CD4% at baseline was available for 2119 individuals.
i CD4 cell count at ART initiation was available for 2127 individuals.
j CD4% at ART initiation was available for 2074 individuals.
k Use of antituberculous drugs was available for 3097 individuals.
l Platelet count was available for 2993 individuals.
m AST was available for 2993 individuals.
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Table 2. APRI Score at Baseline (n = 1707) and at 12–24 Months (n = 1106)
APRI Score
Baseline 12–24 Months Post-ART
All (n = 1707) HIV Monoinfected (n = 1566) HBV/HIV Coinfected (n = 141) P Value All (n = 1106) HIV Monoinfected (n = 1050) HBV/HIV Coinfected (n = 56) P Value
APRI, median (IQR) 0.38 (0.22–0.79) 0.37 (0.22–0.77) 0.57 (0.32–1.08) <.001 0.41 (0.23–0.77) 0.40 (0.22–0.77) 0.50 (0.28–0.93) .05
APRI > 1.5, n (%) 156 (9.1) 136 (8.7) 20 (14.2) .03 56 (5.1) 51 (5.0) 5 (5.8) .74
APRI > 2, n (%) 90 (5.3) 77 (4.9) 13 (9.2) .03 26 (2.4) 22 (2.2) 4 (4.7) .14
Abbreviations: APRI, AST-to-platelet ratio index; ART, antiretroviral therapy; HBV, hepatitis B infection; HIV, human immunodeficiency virus; IQR, interquartile range.
Table 3. Correlates of Pre-ART Liver Fibrosis and Cirrhosis (n = 1707)
Characteristic
Significant Fibrosis (APRI > 1.5) Cirrhosis (APRI > 2)
n/Na
Univariate Multivariable
n/N
Univariate Multivariable
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
HBV test .03 .22 .03 .13
Negative 136/1566 1 1 77/1566 1 1
Positive 20/141 1.73 (1.05–2.88) 1.44 (.81–2.59) 13/141 1.96 (1.06–3.63) 1.71 (.85–3.46)
CD4 cell count .002 .01 .04 .05
CD4 > 200 cells/μL 42/597 1 1 24/597 1 1
CD4 < 200 cells/μL 92/757 1.82 (1.25–2.68) 1.72 (1.16–2.54) 50/757 1.69 (1.03–2.78) 1.64 (.99–2.72)
Alcohol consumption .01 .03 .01 .04
No 101/1257 1 1 58/1257 1 1
Yes 46/369 1.63 (1.13–2.36) 1.60 (1.06–2.40) 29/367 1.76 (1.11–2.78) 1.72 (1.03–2.87)
Abbreviations: APRI, AST-to-platelet ratio index; CI, confidence intervals; HBV, hepatitis B infection; HIV, human immunodeficiency virus.
a n/N is the number of HIV individuals with significant fibrosis-cirrhosis/total number of HIV individuals for a specific category.
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The prevalence of HBsAg positivity was 7.3% (95% CI,
6.4–8.2), consistent with previous studies from sub-Saharan
countries [2] and particularly from Tanzanian studies where
the prevalence of HBV infection among PLWHIV ranged
from 3.2% to 17.3% [1]. Similar to the results from a large
Zambian cohort [22], the overall baseline prevalence of pre-
ART APRI score indicating signiﬁcant ﬁbrosis (APRI > 1.5)
and cirrhosis (APRI > 2) was 9.1% and 5.3%, respectively. In
the Multicentre AIDS Cohort Study, baseline hepatic ﬁbrosis
score assessed by APRI was signiﬁcantly higher in HIV-positive
individuals with either HBV or HCV coinfection compared
with those with HIV-monoinfection [23]. In our cohort, both
APRI score indicating signiﬁcant ﬁbrosis and cirrhosis (14.2%
and 9.2%, respectively) were more prevalent among HIV/
HBV-coinfected individuals. As also seen in studies from
high-income countries [23, 24] and sub-Saharan countries
[14, 15], we found a signiﬁcant association between HBV infec-
tion and liver ﬁbrosis. However, after adjusting for CD4, age,
gender, and alcohol consumption, the strength and precision
of this association decreased.
A majority of HIV-individuals from our cohort did not
exhibit APRI score variation after 12–24 months on ART. It
is remarkable that among HIV-individuals with APRI score
indicating signiﬁcant ﬁbrosis, more than 90% presented a
regression to APRI < 1.5 12–24 months after ART initiation.
The regression of APRI score was particularly evident among
HIV-monoinfected individuals. However, whether ART-
induced regression of liver ﬁbrosis is more likely in HIV-
monoinfected compared with HIV/HBV-coinfected remains
unclear. Although treatment for chronic HBV infection with
3TC and TDF has shown its efﬁcacy in reducing and even
regressing liver histological ﬁbrosis [16, 25, 26], more data are
needed to determine whether HBV treatment will have similar
effects in sub-Saharan African populations.
The APRI has been endorsed by the WHO using a single
high cutoff >2 for cirrhosis as key criteria for prioritizing
initiation of ART in resource-constrained settings [11]. The
diagnostic accuracy for hepatic ﬁbrosis using APRI has been
widely investigated in HBV-monoinfected [27] and less
frequently in ART-naive HIV-monoinfected and HIV/HBV-
coinfected individuals from high-income countries [22, 23,
28]. However, although APRI is cheap and accessible, it is not
an optimal test for liver ﬁbrosis assessment when compared
with TE, which has exhibited better accuracy particularly in
HIV/HBV-coinfected individuals [14, 29]. For instance, APRI
has demonstrated a low sensitivity for detecting liver cirrhosis
in some African studies when applying the WHO cutoff [30].
An important challenge with the use of APRI in HIV/HBV-
coinfected individuals is the interpretation of ﬁbrosis change
over time: ART often reverses HIV-associated thrombocytope-
nia and liver transaminases values. Thus, it is impossible to
know whether changes in APRI after ART start correspond
to hepatic inﬂammation decrease or true histological regression
of ﬁbrosis. Very few studies have shown histological regression
of HBV-related ﬁbrosis on treatment, and these changes started
to occur from after 24 to 48 months [31, 32]. In our cohort, only
10% of all participants had low PLT at baseline and AST eleva-
tions were rare, but we are conﬁdent that this was not a major
issue in our study. In addition, APRI score values might be over-
estimated by thrombocytopenia and liver inﬂammation second-
ary to opportunistic infections, especially tuberculosis and its
treatment. In our study, none of the patients included in the
APRI regression analysis was on anti-TB drugs. In addition,
in a previous study, we demonstrated the absence of hepatitis
delta coinfection [20] among HIV/HBV-coinfected individuals
from our cohort. Whereas the effect of these confounders
when assessing liver ﬁbrosis using APRI score in Africa are
still unknown, a novel noninvasive test, the γ-glutamyl trans-
peptidase-to-platelet ratio, was recently shown to have better
accuracy than APRI for identifying signiﬁcant liver ﬁbrosis in
HBV-monoinfected patients [30]. Its performance in SSA has
not yet been elucidated [33], but it did not show a good enough
positive predictive value in other western cohorts to be consid-
ered as a recommended biomarker in HIV/HBV-coinfected
patients [34].
CD4 cell count of <200 cells/µL before ART initiation was
associated with an increased risk of APRI score indicating sig-
niﬁcant ﬁbrosis and cirrhosis, as expected, because previous
studies have shown that HIV-related immunosuppression
could lead to a more rapid progression to liver ﬁbrosis and
cirrhosis in coinfected individuals [35, 36]. Consumption of
alcohol was also a predictors in our cohort for having APRI
Figure 1. Aspartate aminotransferase-to-platelet ratio index (APRI) score change
at 12–24 months after antiretroviral therapy (ART) initiation for all individuals with
both pre- and post-ART APRI (n = 500).
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score indicating signiﬁcant ﬁbrosis and cirrhosis. Alcohol con-
sumption is indeed a well known risk factor for liver ﬁbrosis,
and it is common in Eastern Africa especially among young
people [37]. However, the heterogeneity of instruments used
for the screening and assessment of alcohol consumption in
other studies and the fact that we did not use WHO-validated
and WHO-recommended tests such as AUDIT make it difﬁcult
to evaluate whether our results on alcohol use prevalence are
higher than [7] or similar [14] to others.
This study has some limitations. First, <20% of all eligible
individuals were available for the APRI score variation analysis,
resulting in a limited number of individuals included in the
analysis and a reduced strength of our results. However, the
exclusion of a large proportion of patients from the longitudinal
analyses may not have biased our results, because the main
demographic and clinical characteristics of these patients were
similar to the ones of the analysis cohort. Second, we could
not properly characterize HBV infection with additional HBV
serological markers such as HBeAg and quantiﬁcation of
HBV deoxyribonucleic acid levels, 2 well known predictors of
liver disease in HBsAg-positive patients. In addition, HCV-
infection screening was not performed and thus could not be
included in our logistic regression analysis. Nevertheless, several
studies in SSA exhibited a low prevalence or absence of anti-
HCV in HIV-infected individuals [7, 38], including a previous
study conducted in our setting [4]. Finally, information on
other well known risk factors for liver ﬁbrosis such as aﬂatoxin
levels, use of traditional herbal medicine, and microbiological
tests to exclude endemic infections such as malaria or schisto-
somiasis were not assessed, and we cannot exclude residual
confounding.
CONCLUSIONS
In conclusion, our study is among the ﬁrst assessing APRI score
variation after ART initiation in SSA. Our data showed a con-
siderable proportion of HIV-individuals presenting with liver
ﬁbrosis in whom APRI score regressed after ART initiation.
This study highlights the need for speciﬁc national guidelines
on the management of HBV/HIV coinfection in areas of high
HBV endemicity. Further research is required to better charac-
terize HBV liver-related ﬁbrosis, which remains a necessity to
monitor and prevent evolution towards end-stage liver diseases.
Efforts must be placed in comparing accuracy of different non-
invasive tests in this population, in ﬁnding more reliable mark-
ers of hepatic ﬁbrosis, and in implementing optimal screening
methods for HCC, given that HBV the is leading causative agent
in the sub-Saharan region.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseases
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